assessing drugs for reimbursement in québec public health...
TRANSCRIPT
![Page 1: Assessing Drugs for Reimbursement in Québec Public Health ...redetsa.org/wp/wp-content/uploads/2017/02/8-INESSS_20161129-SA… · Concepts, strategies and challenges Stéphane P](https://reader035.vdocuments.mx/reader035/viewer/2022071004/5fc1777094bfcd044748423a/html5/thumbnails/1.jpg)
Assessing Drugs for Reimbursement in Québec Public Health Programs: Concepts, strategies and challenges
Stéphane P. Ahern, m.d. Ph.DChairComité scientifique pour l’évaluation des médicaments pour fins d’inscription
November 29, 2016
![Page 2: Assessing Drugs for Reimbursement in Québec Public Health ...redetsa.org/wp/wp-content/uploads/2017/02/8-INESSS_20161129-SA… · Concepts, strategies and challenges Stéphane P](https://reader035.vdocuments.mx/reader035/viewer/2022071004/5fc1777094bfcd044748423a/html5/thumbnails/2.jpg)
2
Objectives
• Understand the mechanism of assessment of drug in order to make recommendations to the Minister with view to updating the list of medications;
• Explore some of the recommendation scheme the Institute use in order to take into account clinical, economical and/or organizational uncertainty with regard to particular drug
• Discuss some of the analytical and deliberation issues arising within the Committee.
![Page 3: Assessing Drugs for Reimbursement in Québec Public Health ...redetsa.org/wp/wp-content/uploads/2017/02/8-INESSS_20161129-SA… · Concepts, strategies and challenges Stéphane P](https://reader035.vdocuments.mx/reader035/viewer/2022071004/5fc1777094bfcd044748423a/html5/thumbnails/3.jpg)
3
Plan
• Contextual Issues regarding the list of medications (in Hospital and Public Drug Insurance Plan)
• Legal Context, specific to Québec • Scientific Evaluation Process • Ethical challenges related to drug assessment
![Page 4: Assessing Drugs for Reimbursement in Québec Public Health ...redetsa.org/wp/wp-content/uploads/2017/02/8-INESSS_20161129-SA… · Concepts, strategies and challenges Stéphane P](https://reader035.vdocuments.mx/reader035/viewer/2022071004/5fc1777094bfcd044748423a/html5/thumbnails/4.jpg)
4
MISSION
The mission of the institute is to promoteclinical excellence and the efficient use of resources inthe health and social services sector.
INESSS
![Page 5: Assessing Drugs for Reimbursement in Québec Public Health ...redetsa.org/wp/wp-content/uploads/2017/02/8-INESSS_20161129-SA… · Concepts, strategies and challenges Stéphane P](https://reader035.vdocuments.mx/reader035/viewer/2022071004/5fc1777094bfcd044748423a/html5/thumbnails/5.jpg)
5
PrinciplesExcellence IndependenceOpenness
Scientific RigourTransparencyIntegrityEquity
INESSS
![Page 6: Assessing Drugs for Reimbursement in Québec Public Health ...redetsa.org/wp/wp-content/uploads/2017/02/8-INESSS_20161129-SA… · Concepts, strategies and challenges Stéphane P](https://reader035.vdocuments.mx/reader035/viewer/2022071004/5fc1777094bfcd044748423a/html5/thumbnails/6.jpg)
6
Health Insurance Plan
A Basic Prescription Drug Insurance Plan The purpose of the basic plan is to ensure that all persons inQuébec have reasonable and fair access to the medicationrequired by their state of health.
To that end, the plan provides for a minimum level of coveragefor the cost of pharmaceutical services and medications, andrequires a financial participation on the part of persons orfamilies covered by the plan depending, in particular, on theireconomic situation.http://www.canlii.org/en/qc/laws/stat/cqlr‐c‐a‐29.01/latest/cqlr‐c‐a‐29.01.html
![Page 7: Assessing Drugs for Reimbursement in Québec Public Health ...redetsa.org/wp/wp-content/uploads/2017/02/8-INESSS_20161129-SA… · Concepts, strategies and challenges Stéphane P](https://reader035.vdocuments.mx/reader035/viewer/2022071004/5fc1777094bfcd044748423a/html5/thumbnails/7.jpg)
7
BPDIP Objectives and characteristics
Objectives• Equitable and affordable access to prescribed drugs • Shared cost between users • Integrated scheme of reimbursement
Characteristics : • Universal • Mixt • Contributive• Mandatory
![Page 8: Assessing Drugs for Reimbursement in Québec Public Health ...redetsa.org/wp/wp-content/uploads/2017/02/8-INESSS_20161129-SA… · Concepts, strategies and challenges Stéphane P](https://reader035.vdocuments.mx/reader035/viewer/2022071004/5fc1777094bfcd044748423a/html5/thumbnails/8.jpg)
8
Shared Decision Making
RAMQ
CABINETDU MINISTRE
MMIINNIISSTTRREEDDEE LLAA SSAANNTTÉÉ EETT DDEESSSSEERRVVIICCEESS SSOOCCIIAAUUXX
INESSS MSSS AUTRES
![Page 9: Assessing Drugs for Reimbursement in Québec Public Health ...redetsa.org/wp/wp-content/uploads/2017/02/8-INESSS_20161129-SA… · Concepts, strategies and challenges Stéphane P](https://reader035.vdocuments.mx/reader035/viewer/2022071004/5fc1777094bfcd044748423a/html5/thumbnails/9.jpg)
9
Shared Responsibilities
• Ministry of Health : the final decision maker After receiving the recommendations of INESSS, the Ministry of Health
decide which drug will be list or not
• Ministry of Health: – Following drug utilization patterns and costs – Elaborate guiding policies regarding drug uses in Québec – Create a collaborative process between all stakeholders – Responsible for the inscription agreement plan
![Page 10: Assessing Drugs for Reimbursement in Québec Public Health ...redetsa.org/wp/wp-content/uploads/2017/02/8-INESSS_20161129-SA… · Concepts, strategies and challenges Stéphane P](https://reader035.vdocuments.mx/reader035/viewer/2022071004/5fc1777094bfcd044748423a/html5/thumbnails/10.jpg)
10
Shared Responsabilities
• INESSS– Make recommendation based on robust scientific and holistic
evaluation of the drug – Assess proper optimal usage of drug
![Page 11: Assessing Drugs for Reimbursement in Québec Public Health ...redetsa.org/wp/wp-content/uploads/2017/02/8-INESSS_20161129-SA… · Concepts, strategies and challenges Stéphane P](https://reader035.vdocuments.mx/reader035/viewer/2022071004/5fc1777094bfcd044748423a/html5/thumbnails/11.jpg)
11
Legal Context
![Page 12: Assessing Drugs for Reimbursement in Québec Public Health ...redetsa.org/wp/wp-content/uploads/2017/02/8-INESSS_20161129-SA… · Concepts, strategies and challenges Stéphane P](https://reader035.vdocuments.mx/reader035/viewer/2022071004/5fc1777094bfcd044748423a/html5/thumbnails/12.jpg)
12
Contexte législatif des listes de médicaments
ACT RESPECTING THE INSTITUT NATIONAL D’EXCELLENCE EN SANTÉ ET EN SERVICES SOCIAUX
7. In exercising the functions described in paragraph 8 of section 5, the institute must first assess the therapeutic value of a medication. If this is not established to its satisfaction, the institute sends a notice to that effect to the Minister.If the institute considers that the therapeutic value of a medication has been established, it sends its recommendation to the Minister after assessing(1) the reasonableness of the price charged;(2) the cost‐effectiveness ratio of the medication;(3) the impact that entering the medication on the list will have on the health of the general public and on the other components of the health and social services system; and(4) the advisability of entering the medication on the list, given the purpose of the basic prescription drug insurance plan.
![Page 13: Assessing Drugs for Reimbursement in Québec Public Health ...redetsa.org/wp/wp-content/uploads/2017/02/8-INESSS_20161129-SA… · Concepts, strategies and challenges Stéphane P](https://reader035.vdocuments.mx/reader035/viewer/2022071004/5fc1777094bfcd044748423a/html5/thumbnails/13.jpg)
13
Scientific Evaluation Process
![Page 14: Assessing Drugs for Reimbursement in Québec Public Health ...redetsa.org/wp/wp-content/uploads/2017/02/8-INESSS_20161129-SA… · Concepts, strategies and challenges Stéphane P](https://reader035.vdocuments.mx/reader035/viewer/2022071004/5fc1777094bfcd044748423a/html5/thumbnails/14.jpg)
14
Scientific Evaluation Process
• Public Evaluation Process
• Specific assessment modalities
• Public Requirements
• New Guidance in 2012 for Oncology drugs
![Page 15: Assessing Drugs for Reimbursement in Québec Public Health ...redetsa.org/wp/wp-content/uploads/2017/02/8-INESSS_20161129-SA… · Concepts, strategies and challenges Stéphane P](https://reader035.vdocuments.mx/reader035/viewer/2022071004/5fc1777094bfcd044748423a/html5/thumbnails/15.jpg)
15
Calendar
• New innovative drugs (3 lists per year, since 2003)• Generic Multisources Drugs (7 lists per year) • 400‐500 drugs assess per year • Clinical and economical assessment possible
![Page 16: Assessing Drugs for Reimbursement in Québec Public Health ...redetsa.org/wp/wp-content/uploads/2017/02/8-INESSS_20161129-SA… · Concepts, strategies and challenges Stéphane P](https://reader035.vdocuments.mx/reader035/viewer/2022071004/5fc1777094bfcd044748423a/html5/thumbnails/16.jpg)
16
Priority Evaluation
Therapeutic Goal – No option available – Delay might cause significant harms
Economic goal – Potential saving of minimum of 200 000 $/month
![Page 17: Assessing Drugs for Reimbursement in Québec Public Health ...redetsa.org/wp/wp-content/uploads/2017/02/8-INESSS_20161129-SA… · Concepts, strategies and challenges Stéphane P](https://reader035.vdocuments.mx/reader035/viewer/2022071004/5fc1777094bfcd044748423a/html5/thumbnails/17.jpg)
17
Drug Assessment Committee
2 scientists (pharmacoeconomist, statistician)10 clinicians (family physicians, specialists and hospital pharmacists)1 health administrator 2 ethicists 2 citizens
![Page 18: Assessing Drugs for Reimbursement in Québec Public Health ...redetsa.org/wp/wp-content/uploads/2017/02/8-INESSS_20161129-SA… · Concepts, strategies and challenges Stéphane P](https://reader035.vdocuments.mx/reader035/viewer/2022071004/5fc1777094bfcd044748423a/html5/thumbnails/18.jpg)
18
INESSSConseil d’administration
Vice‐présidente production scientifique
Direction de l’évaluation des médicaments aux fins d’inscription
Comité scientifique de l’évaluation des médicaments aux fins d’inscription (CSEMI)
Experts externes
ÉQUIPE DE ≥ 4 ÉVALUATEURS /médicament
11 membres
17 membres
Groupe de travail et comité
18 professionnels
Assessment Pathway
18
![Page 19: Assessing Drugs for Reimbursement in Québec Public Health ...redetsa.org/wp/wp-content/uploads/2017/02/8-INESSS_20161129-SA… · Concepts, strategies and challenges Stéphane P](https://reader035.vdocuments.mx/reader035/viewer/2022071004/5fc1777094bfcd044748423a/html5/thumbnails/19.jpg)
19
Type of demand
• New drug• New indication for limited medication access • New medication association • New medication formulation • Dressings, enteral nutrition, natural products (special consideration)
• Multisource generic drug
19
![Page 20: Assessing Drugs for Reimbursement in Québec Public Health ...redetsa.org/wp/wp-content/uploads/2017/02/8-INESSS_20161129-SA… · Concepts, strategies and challenges Stéphane P](https://reader035.vdocuments.mx/reader035/viewer/2022071004/5fc1777094bfcd044748423a/html5/thumbnails/20.jpg)
20
Specific Drug Requirements
• Homologation Compliance Information– Clinical Data Summary– Health Canada Reviewers – Monography
• Clinical studies • Price and justification• Pharmacoeconomic studies • Budget Impact Analysis • Promotional material
20
![Page 21: Assessing Drugs for Reimbursement in Québec Public Health ...redetsa.org/wp/wp-content/uploads/2017/02/8-INESSS_20161129-SA… · Concepts, strategies and challenges Stéphane P](https://reader035.vdocuments.mx/reader035/viewer/2022071004/5fc1777094bfcd044748423a/html5/thumbnails/21.jpg)
21
Drug Assessment
Therapeutic Value • Critical first step in the evaluation process
• Efficacy ≠Therapeu c Value – Therapeutic Value
• Efficacy• Safety• Therapeutic advantages • Adherence
![Page 22: Assessing Drugs for Reimbursement in Québec Public Health ...redetsa.org/wp/wp-content/uploads/2017/02/8-INESSS_20161129-SA… · Concepts, strategies and challenges Stéphane P](https://reader035.vdocuments.mx/reader035/viewer/2022071004/5fc1777094bfcd044748423a/html5/thumbnails/22.jpg)
22
Drug Assessment (TV)
• Evidence Based Decision Making – 1 RCT – Other clinical information – Review of the literature made by INESSS – Meta‐analysis – Guidelines – Santé Canada, FDA, NICE, ACMTS, HAS, …
![Page 23: Assessing Drugs for Reimbursement in Québec Public Health ...redetsa.org/wp/wp-content/uploads/2017/02/8-INESSS_20161129-SA… · Concepts, strategies and challenges Stéphane P](https://reader035.vdocuments.mx/reader035/viewer/2022071004/5fc1777094bfcd044748423a/html5/thumbnails/23.jpg)
23
Drug Assessment TV
• Critical Appraisal of Submitted Studies– Level of evidence / reliability / validity / bias – Relevance of the study population to our clinical context e– Comparator – Significant Clinical Outcomes
– Unmet clinical needs paradigm
![Page 24: Assessing Drugs for Reimbursement in Québec Public Health ...redetsa.org/wp/wp-content/uploads/2017/02/8-INESSS_20161129-SA… · Concepts, strategies and challenges Stéphane P](https://reader035.vdocuments.mx/reader035/viewer/2022071004/5fc1777094bfcd044748423a/html5/thumbnails/24.jpg)
24
Évaluation des médicaments
Valeur thérapeutique de chaque médicament• Appréciation de l’ensembles des résultats
– Résultats (statistiques) – Signification clinique– NNH et NNT si pertinents– Ampleur des résultats
• Concordance entre les résultats des études retenues• Expertise clinique• Pertinence clinique• Besoin de santé non comblé
![Page 25: Assessing Drugs for Reimbursement in Québec Public Health ...redetsa.org/wp/wp-content/uploads/2017/02/8-INESSS_20161129-SA… · Concepts, strategies and challenges Stéphane P](https://reader035.vdocuments.mx/reader035/viewer/2022071004/5fc1777094bfcd044748423a/html5/thumbnails/25.jpg)
25
Évaluation des médicaments
Justesse du prix• Comparaison du coût du traitement p/r comparateurs
– Basée sur le PVG du fabricant ou le prix aux établissements
• Évaluation du coût du traitement – par rapport aux coûts d’autres stratégies, médicamenteusesou non, à même visée thérapeutique;
– sans le coût des services professionnels du pharmacien saufexceptions;
– sans soustraction des contributions monétaires des assurés.
![Page 26: Assessing Drugs for Reimbursement in Québec Public Health ...redetsa.org/wp/wp-content/uploads/2017/02/8-INESSS_20161129-SA… · Concepts, strategies and challenges Stéphane P](https://reader035.vdocuments.mx/reader035/viewer/2022071004/5fc1777094bfcd044748423a/html5/thumbnails/26.jpg)
26
Drug Assessment : Effectiveness
Cost Efficacy Ratio and Pricing
• Pharmaco‐economic studies • CADTH methodological requirements • Different models for different clinical context
– Cost Efficacy Studies– Cost Utility Studies – Cost Minimization Studies – Cost Consequences Studies
![Page 27: Assessing Drugs for Reimbursement in Québec Public Health ...redetsa.org/wp/wp-content/uploads/2017/02/8-INESSS_20161129-SA… · Concepts, strategies and challenges Stéphane P](https://reader035.vdocuments.mx/reader035/viewer/2022071004/5fc1777094bfcd044748423a/html5/thumbnails/27.jpg)
27
DRUG ASSESSMENT : EFFECTIVENESS
• Societal Perspective as a primary model • Critical appraisal of the clinical modelization and the clinical hypothesis
• Different indicators are considered • Uncertainty • No specific threshold is considered cost effective
![Page 28: Assessing Drugs for Reimbursement in Québec Public Health ...redetsa.org/wp/wp-content/uploads/2017/02/8-INESSS_20161129-SA… · Concepts, strategies and challenges Stéphane P](https://reader035.vdocuments.mx/reader035/viewer/2022071004/5fc1777094bfcd044748423a/html5/thumbnails/28.jpg)
28
Étude coût- utilité
Ratio coût-utilité différentiel de Diacomitmc en traitement d’appoint au clobazam et au valproatecomparativement à l’association de ces derniers pour le traitement des crises épileptiquesgénéralisées tonico-cloniques réfractaires du syndrome de Dravet
PerspectiveFabricant INESSS
QALY différentiel
Coûts différentiels
Ratio coût‐utilité différentiel
Ratio coût‐utilité différentiel
Ministère de la santé 0,69 34 750 $ 50 069 $/QALY gagné
De dominanta à 67 000 $/QALY
gagné
Sociétale 0,69 ‐27 100 $ Dominanta
Analyses de sensibilité
Déterministeb
Probabilistec
De dominanta à 113 791 $/QALY gagné
La probabilité est de 100 % que le ratio soit inférieur à 50 000 $/QALY gagné et de 100 % qu’il soit inférieur à 100 000 $/QALY gagné.
![Page 29: Assessing Drugs for Reimbursement in Québec Public Health ...redetsa.org/wp/wp-content/uploads/2017/02/8-INESSS_20161129-SA… · Concepts, strategies and challenges Stéphane P](https://reader035.vdocuments.mx/reader035/viewer/2022071004/5fc1777094bfcd044748423a/html5/thumbnails/29.jpg)
29
Analyse de minimisation de coûts: Glycopyrronium contre tiotropium
BronchodilatateurDose quotidienne recommandée
Coût annuel
Fabricant INESSSa
Glycopyrronium(Seebri BreezhalerMC) 50 mcg xxx $
(xxx $/ jour)646,05 $
(1,77 $/ jour)
Tiotropium(SpirivaMC
HandiHalerMC)18 mcg xxx $
(xxx $/ jour)766,50 $(2,10 $/ jour)
a Coût établi selon le prix de la Liste de médicaments d’avril 2013 ou selon le prix soumis par lefabricant, excluant celui des services professionnels du pharmacien et la marge bénéficiaire dugrossiste
Analyse de minimisation des coûts comparant le glycopyrroniumau tiotropium pour le traitement de la MPOC modérée ou grave chez l’adulte
![Page 30: Assessing Drugs for Reimbursement in Québec Public Health ...redetsa.org/wp/wp-content/uploads/2017/02/8-INESSS_20161129-SA… · Concepts, strategies and challenges Stéphane P](https://reader035.vdocuments.mx/reader035/viewer/2022071004/5fc1777094bfcd044748423a/html5/thumbnails/30.jpg)
30
Analyse de minimisation des coûts: Comparaison mirabegron et antimuscariniques
MédicamentCoût de traitement annuel
Fabricant INESSSa
Mirabegron xxx $ 548 $
Fésotérodine xxx $ 548 $Oxybutynine(libérationimmédiate) xxx $b s.o.c
Oxybutynine(libérationprolongée) xxx $d à xxx $e 669 $ à 674 $f
Solifénacine xxx $ 548 $
Toltérodine xxx $ 691 $
Trospium xxx $ à 832 $ 277 $ à 554 $
Coût moyen pondéré 619 $ 638 $g
![Page 31: Assessing Drugs for Reimbursement in Québec Public Health ...redetsa.org/wp/wp-content/uploads/2017/02/8-INESSS_20161129-SA… · Concepts, strategies and challenges Stéphane P](https://reader035.vdocuments.mx/reader035/viewer/2022071004/5fc1777094bfcd044748423a/html5/thumbnails/31.jpg)
31
Drug Assessment
The impact that entering the medication on the list will have on the health of the general public and on the other components of the health and social services system
• Disease Burden • Prevalence • Social aspects of the disease• Overall Economic and Resources Impact • Holistic Evaluation • Patient’s and Clinician’s Perspectives •
![Page 32: Assessing Drugs for Reimbursement in Québec Public Health ...redetsa.org/wp/wp-content/uploads/2017/02/8-INESSS_20161129-SA… · Concepts, strategies and challenges Stéphane P](https://reader035.vdocuments.mx/reader035/viewer/2022071004/5fc1777094bfcd044748423a/html5/thumbnails/32.jpg)
32
Évaluation des médicaments
Analyse d’impact net
• Répercussions économiques ou non économiques de l’inscription
• Mise en parallèle de l’apport thérapeutique et des répercussions économiques
• Données d’utilisation des ressources de santé
• Description détaillée si non monétaire
• Exemples: Pradaxa, Coaguchek, Eliquis
32
![Page 33: Assessing Drugs for Reimbursement in Québec Public Health ...redetsa.org/wp/wp-content/uploads/2017/02/8-INESSS_20161129-SA… · Concepts, strategies and challenges Stéphane P](https://reader035.vdocuments.mx/reader035/viewer/2022071004/5fc1777094bfcd044748423a/html5/thumbnails/33.jpg)
33
Drug Assessment : Societal Perspective
Budget Impact Analysis
• Identification of the target population in Québec
• Economic impact on the public regime
• Economic impact for the hospital
• 3 periods of 12 months each
33
![Page 34: Assessing Drugs for Reimbursement in Québec Public Health ...redetsa.org/wp/wp-content/uploads/2017/02/8-INESSS_20161129-SA… · Concepts, strategies and challenges Stéphane P](https://reader035.vdocuments.mx/reader035/viewer/2022071004/5fc1777094bfcd044748423a/html5/thumbnails/34.jpg)
34
Évaluation des médicaments
Évaluation économique
• Ressources restreintes• Choix• Coût d’opportunité• Capacité de payer :
– du citoyen;– de l’hôpital;– de l’agent payant;– de la société.
34
![Page 35: Assessing Drugs for Reimbursement in Québec Public Health ...redetsa.org/wp/wp-content/uploads/2017/02/8-INESSS_20161129-SA… · Concepts, strategies and challenges Stéphane P](https://reader035.vdocuments.mx/reader035/viewer/2022071004/5fc1777094bfcd044748423a/html5/thumbnails/35.jpg)
35
Drug Assessment
The advisability of entering the medication on the list, given the purpose of the basic prescription drug insurance plan.
• Ethical considerations• Societal Values and Preferences • Reasonableness and Affordability
![Page 36: Assessing Drugs for Reimbursement in Québec Public Health ...redetsa.org/wp/wp-content/uploads/2017/02/8-INESSS_20161129-SA… · Concepts, strategies and challenges Stéphane P](https://reader035.vdocuments.mx/reader035/viewer/2022071004/5fc1777094bfcd044748423a/html5/thumbnails/36.jpg)
36
Drug Assessment
Example of ethical and societal considerationsBotox (Hyperactivité vésicale – SEP et lésion cervicale)
– Continence urinaire – impacts sociauxLucentis (DMLA)
– Acuité visuelle – autonomie – permis de conduireRevlimid (anémie ‐ SMD)
– Transfusions sanguinesToctino (eczéma grave des mains)
– Conséquences sur la vie quotidienne et professionnelle
![Page 37: Assessing Drugs for Reimbursement in Québec Public Health ...redetsa.org/wp/wp-content/uploads/2017/02/8-INESSS_20161129-SA… · Concepts, strategies and challenges Stéphane P](https://reader035.vdocuments.mx/reader035/viewer/2022071004/5fc1777094bfcd044748423a/html5/thumbnails/37.jpg)
37
Values, Drug and Society
AffordableAccess
Distributive Justice
Solidarity
Equity
Autonomy and Self Determination
Procedural Justice
Risk Sharing Approach and Uncertainty
![Page 38: Assessing Drugs for Reimbursement in Québec Public Health ...redetsa.org/wp/wp-content/uploads/2017/02/8-INESSS_20161129-SA… · Concepts, strategies and challenges Stéphane P](https://reader035.vdocuments.mx/reader035/viewer/2022071004/5fc1777094bfcd044748423a/html5/thumbnails/38.jpg)
38
Deliberation (discussion)
Within the Committee• Data presentation and conclusion of the working group • Appraisal of the clinical context and specific disease • Therapeutic value and differential elements • Choice of the pharmacoeconomic model • Overall impact analysis • Scoring of the different criteria • Recommendation and judgment formulation
![Page 39: Assessing Drugs for Reimbursement in Québec Public Health ...redetsa.org/wp/wp-content/uploads/2017/02/8-INESSS_20161129-SA… · Concepts, strategies and challenges Stéphane P](https://reader035.vdocuments.mx/reader035/viewer/2022071004/5fc1777094bfcd044748423a/html5/thumbnails/39.jpg)
39
Just Caring L.M. Fleck
• If we had unlimited sums of money for meeting health care needs, then there would be no need for priority setting.But no magic wand exists that creates money for nothing. (…) What does is mean to be a just and caring society when we have only limited resources to meet virtually unlimited health care needs? (page 5).
![Page 40: Assessing Drugs for Reimbursement in Québec Public Health ...redetsa.org/wp/wp-content/uploads/2017/02/8-INESSS_20161129-SA… · Concepts, strategies and challenges Stéphane P](https://reader035.vdocuments.mx/reader035/viewer/2022071004/5fc1777094bfcd044748423a/html5/thumbnails/40.jpg)
40
Deliberative process
Therapeuticvalue
Price
EffectivenessOpportunities
Éthique et société
Unmet medicalneeds
Equity and reasonable
Overall impact on theSystem
Clinical uncertainty
Industry drivenIndividualSociety
Justice and Fairness
![Page 41: Assessing Drugs for Reimbursement in Québec Public Health ...redetsa.org/wp/wp-content/uploads/2017/02/8-INESSS_20161129-SA… · Concepts, strategies and challenges Stéphane P](https://reader035.vdocuments.mx/reader035/viewer/2022071004/5fc1777094bfcd044748423a/html5/thumbnails/41.jpg)
41
Quelques exemplesValeur thérapeutique
Coût Rapport coût efficacité
Impactbudgétaire
Coût opportunité / Enjeux particuliers
VimizimElosulfase alphaSynd. Morquio
Haut répondeur dans les 2 groupes
TM6M 22 m
500 000 à 800 000 $ selon le poids
Incertain Faible; nombre de patients limités
Solidarité Besoins en réadaptation
Soliris ™ EculizumabHPN
Cochrane Database Syst Rev.2014 Oct 30
500 000$ annuellement
Incertain Faible; nombre de patients limités
Greffe de moelle vs risque vs qualité de vie
Harvoni™ SVR = 96‐98% 44 000 – 134 000$ Selon la sévérité de la maladie, mais coût efficace de F0 à F4
350 X106 à1 X109
![Page 42: Assessing Drugs for Reimbursement in Québec Public Health ...redetsa.org/wp/wp-content/uploads/2017/02/8-INESSS_20161129-SA… · Concepts, strategies and challenges Stéphane P](https://reader035.vdocuments.mx/reader035/viewer/2022071004/5fc1777094bfcd044748423a/html5/thumbnails/42.jpg)
42
Recommendations
• Regular List – no restriction
• Exception List – specific reimbursement criteria
• With Condition and Follow‐Up
• Dismissal
Final decision is made by the Minister of Health
42
![Page 43: Assessing Drugs for Reimbursement in Québec Public Health ...redetsa.org/wp/wp-content/uploads/2017/02/8-INESSS_20161129-SA… · Concepts, strategies and challenges Stéphane P](https://reader035.vdocuments.mx/reader035/viewer/2022071004/5fc1777094bfcd044748423a/html5/thumbnails/43.jpg)
43
Publication des avis au ministre
![Page 44: Assessing Drugs for Reimbursement in Québec Public Health ...redetsa.org/wp/wp-content/uploads/2017/02/8-INESSS_20161129-SA… · Concepts, strategies and challenges Stéphane P](https://reader035.vdocuments.mx/reader035/viewer/2022071004/5fc1777094bfcd044748423a/html5/thumbnails/44.jpg)
44
Questions ?
![Page 45: Assessing Drugs for Reimbursement in Québec Public Health ...redetsa.org/wp/wp-content/uploads/2017/02/8-INESSS_20161129-SA… · Concepts, strategies and challenges Stéphane P](https://reader035.vdocuments.mx/reader035/viewer/2022071004/5fc1777094bfcd044748423a/html5/thumbnails/45.jpg)
45
En collaboration étroite avec Marie Hotte2535, Boul. Laurier 5e étageQuébec (Québec) G1V 4M3
2021 avenue Union, bureau 10.083Montréal (Québec) H3A 2S9